{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:19:41Z","timestamp":1794262781713,"version":"4.9.0"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung cancer remains the leading cause of cancer-related deaths globally, and the survival rate remains low despite advances in diagnosis and treatment. The progression of lung cancer is a multifaceted and dynamic phenomenon that encompasses interplays among cancerous cells and their microenvironment, which incorporates immune cells. Exosomes, which are small membrane-bound vesicles, are released by numerous cell types in normal and stressful situations to allow communication between cells. Tumor-derived exosomes (TEXs) possess diverse neo-antigens and cargoes such as proteins, RNA, and DNA and have a unique molecular makeup reflecting tumor genetic complexity. TEXs contain both immunosuppressive and immunostimulatory factors and may play a role in immunomodulation by influencing innate and adaptive immune components. Moreover, they transmit signals that contribute to the progression of lung cancer by promoting metastasis, epithelial-mesenchymal transition (EMT), angiogenesis, and immunosuppression. This makes them a valuable resource for investigating the immune environment of tumors, which could pave the way for the development of non-invasive biomarkers that could aid in the prognosis, diagnosis, and immunotherapy of lung cancer. While immune checkpoint inhibitor (ICI) immunotherapy has shown promising results in treating initial-stage cancers, most patients eventually develop adaptive resistance over time. Emerging evidence demonstrates that TEXs could serve as a prognostic biomarker for immunotherapeutic response and have a significant impact on both systemic immune suppression and tumor advancement. Therefore, understanding TEXs and their role in lung cancer tumorigenesis and their response to immunotherapies is an exciting research area and needs further investigation. This review highlights the role of TEXs as key contributors to the advancement of lung cancer and their clinical significance in lung immune-oncology, including their possible use as biomarkers for monitoring disease progression and prognosis, as well as emerging shreds of evidence regarding the possibility of using exosomes as targets to improve lung cancer therapy.<\/jats:p>","DOI":"10.1186\/s13046-023-02753-7","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T02:01:44Z","timestamp":1693274504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts"],"prefix":"10.1186","volume":"42","author":[{"given":"Naushad Ahmad","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Asim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir H.","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani N","family":"Alansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harman","family":"Saman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Zahid","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kudaibergen","family":"Osmonaliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-6710","authenticated-orcid":false,"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"1","key":"2753_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2753_CR2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.path.2021.05.002","volume":"14","author":"S Roy-Chowdhuri","year":"2021","unstructured":"Roy-Chowdhuri S. Molecular pathology of lung cancer. Surg Pathol Clin. 2021;14(3):369\u201377.","journal-title":"Surg Pathol Clin"},{"issue":"3","key":"2753_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2753_CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.suc.2021.12.001","volume":"102","author":"AL Oliver","year":"2022","unstructured":"Oliver AL. Lung Cancer: Epidemiology and screening. Surg Clin North Am. 2022;102(3):335\u201344.","journal-title":"Surg Clin North Am"},{"key":"2753_CR5","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, Garc\u00eda-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat. 2020;53:100718.","DOI":"10.1016\/j.drup.2020.100718"},{"key":"2753_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102179","volume":"96","author":"A Addeo","year":"2021","unstructured":"Addeo A, Passaro A, Malapelle U, Banna GL, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021;96: 102179.","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"2753_CR7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/elps.201000598","volume":"32","author":"Y Li","year":"2011","unstructured":"Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis. 2011;32(15):1976\u201383.","journal-title":"Electrophoresis"},{"issue":"6","key":"2753_CR8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40(6):598\u2013610.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2753_CR9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110639","volume":"39","author":"NK Altorki","year":"2022","unstructured":"Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE. Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma. Cell Rep. 2022;39(1): 110639.","journal-title":"Cell Rep"},{"key":"2753_CR10","doi-asserted-by":"crossref","unstructured":"Inamura K. Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma: tumor initiation and progression. Int J Mol Sci. 2018;19(4):1259.","DOI":"10.3390\/ijms19041259"},{"key":"2753_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103393","volume":"163","author":"Y Chen","year":"2021","unstructured":"Chen Y, Wen S, Wu Y, Shi L, Xu X, Shen B. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163: 103393.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2753_CR12","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L. Comparison of efficacy and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Front Immunol. 2021;12: 731546.","journal-title":"Front Immunol"},{"key":"2753_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-030-26439-0_17","volume":"215","author":"I Nazarenko","year":"2020","unstructured":"Nazarenko I. Extracellular vesicles: recent developments in technology and perspectives for cancer liquid biopsy. Recent Results Cancer Res. 2020;215:319\u201344.","journal-title":"Recent Results Cancer Res"},{"key":"2753_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19.","journal-title":"Cell Biosci"},{"key":"2753_CR15","volume":"14","author":"NA Khan","year":"2022","unstructured":"Khan NA, Asim M, El-Menyar A, Biswas KH, Rizoli S, Al-Thani H. The evolving role of extracellular vesicles (exosomes) as biomarkers in traumatic brain injury: Clinical perspectives and therapeutic implications. Front Aging Neurosci. 2022;14: 933434.","journal-title":"Front Aging Neurosci"},{"key":"2753_CR16","volume":"583","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wang Y, Lv Q, Li X. Exosomes: From garbage bins to translational medicine. Int J Pharm. 2020;583: 119333.","journal-title":"Int J Pharm"},{"issue":"2","key":"2753_CR17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188340","volume":"1873","author":"J Da\u00dfler-Plenker","year":"2020","unstructured":"Da\u00dfler-Plenker J, K\u00fcttner V, Egeblad M. Communication in tiny packages: exosomes as means of tumor-stroma communication. Biochim Biophys Acta Rev Cancer. 2020;1873(2): 188340.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2753_CR18","doi-asserted-by":"crossref","unstructured":"Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8(7):727.","DOI":"10.3390\/cells8070727"},{"issue":"11","key":"2753_CR19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14789450.2018.1537788","volume":"15","author":"DW Greening","year":"2018","unstructured":"Greening DW, Simpson RJ. Understanding extracellular vesicle diversity - current status. Expert Rev Proteomics. 2018;15(11):887\u2013910.","journal-title":"Expert Rev Proteomics"},{"issue":"1","key":"2753_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15(1):83.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2753_CR21","first-page":"9811","volume":"15","author":"C Jing","year":"2018","unstructured":"Jing C, Cao H, Qin X, Yu S, Wu J, Wang Z, Ma R, Feng J. Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21. Oncol Lett. 2018;15(6):9811\u20137.","journal-title":"Oncol Lett"},{"key":"2753_CR22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-0759-6_10","volume":"2174","author":"WH Chang","year":"2021","unstructured":"Chang WH, Cerione RA, Antonyak MA. Extracellular vesicles and their roles in cancer progression. Methods Mol Biol. 2021;2174:143\u201370.","journal-title":"Methods Mol Biol"},{"key":"2753_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.phrs.2016.07.006","volume":"111","author":"SAA Kooijmans","year":"2016","unstructured":"Kooijmans SAA, Schiffelers RM, Zarovni N, Vago R. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. Pharmacol Res. 2016;111:487\u2013500.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2753_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12964-019-0390-y","volume":"17","author":"R Rahbarghazi","year":"2019","unstructured":"Rahbarghazi R, Jabbari N, Sani NA, Asghari R, Salimi L, Kalashani SA, Feghhi M, Etemadi T, Akbariazar E, Mahmoudi M, Rezaie J. Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications. Cell Commun Signal. 2019;17(1):73.","journal-title":"Cell Commun Signal"},{"key":"2753_CR25","doi-asserted-by":"crossref","unstructured":"Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, Zar Gul AR, Philip A, Vijayakumar S, Merhi M, Hydrose S, Inchakalody VP, Al-Abdulla R, Abualainin W, Sirriya SA, Al-Bozom I, Uddin S, Khan OM, Mohamed Ibrahim MI, Al Homsi U. and Dermime S. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients. Front Immunol. 2022;13:1097117.","DOI":"10.3389\/fimmu.2022.1097117"},{"issue":"1","key":"2753_CR26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jcb.29323","volume":"121","author":"Y Liao","year":"2020","unstructured":"Liao Y, Cao L, Wang F, Pang R. miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer. J Cell Biochem. 2020;121(1):779\u201387.","journal-title":"J Cell Biochem"},{"issue":"6","key":"2753_CR27","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s10528-022-10191-x","volume":"60","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zheng W, Rao X, Du Y, Xue J. MicroRNA-9-5p facilitates lung adenocarcinoma cell malignant progression via targeting STARD13. Biochem Genet. 2022;60(6):1865\u201380.","journal-title":"Biochem Genet"},{"issue":"17","key":"2753_CR28","doi-asserted-by":"crossref","first-page":"21435","DOI":"10.18632\/aging.203483","volume":"13","author":"H Wen","year":"2021","unstructured":"Wen H, Liu Z, Tang J, Bu L. MiR-185-5p targets RAB35 gene to regulate tumor cell-derived exosomes-mediated proliferation, migration and invasion of non-small cell lung cancer cells. Aging (Albany NY). 2021;13(17):21435\u201350.","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"2753_CR29","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.ymthe.2022.01.046","volume":"30","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, Yu T, Zhang L, Zhu L, Shu Y. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30(10):3133\u201354.","journal-title":"Mol Ther"},{"issue":"1","key":"2753_CR30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-020-02426-5","volume":"18","author":"M Ahmadi","year":"2020","unstructured":"Ahmadi M, Rezaie J. Tumor cells derived-exosomes as angiogenenic agents: possible therapeutic implications. J Transl Med. 2020;18(1):249.","journal-title":"J Transl Med"},{"issue":"9","key":"2753_CR31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41419-021-04037-4","volume":"12","author":"Z Ma","year":"2021","unstructured":"Ma Z, Wei K, Yang F, Guo Z, Pan C, He Y, Wang J, Li Z, Chen L, Chen Y, Xia Y. Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP\/KLF2 in non-small cell lung cancer. Cell Death Dis. 2021;12(9):840.","journal-title":"Cell Death Dis"},{"key":"2753_CR32","doi-asserted-by":"crossref","unstructured":"Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020;21(16):5840.","DOI":"10.3390\/ijms21165840"},{"issue":"1","key":"2753_CR33","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1038\/s41467-018-07810-w","volume":"9","author":"Z Zeng","year":"2018","unstructured":"Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F, Hu J, Zhu X, Yang W, Liao W, Li G, Ding Y, Liang L. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):5395.","journal-title":"Nat Commun"},{"issue":"1","key":"2753_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12943-021-01312-y","volume":"20","author":"MY Li","year":"2021","unstructured":"Li MY, Liu LZ, Dong M. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Mol Cancer. 2021;20(1):22.","journal-title":"Mol Cancer"},{"key":"2753_CR35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fimmu.2018.00819","volume":"9","author":"SD Alipoor","year":"2018","unstructured":"Alipoor SD, Mortaz E, Varahram M, Movassaghi M, Kraneveld AD, Garssen J, Adcock IM. The potential biomarkers and immunological effects of tumor-derived exosomes in lung cancer. Front Immunol. 2018;9:819.","journal-title":"Front Immunol"},{"issue":"2","key":"2753_CR36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2174\/0929867327666200204141952","volume":"28","author":"A Amiri","year":"2021","unstructured":"Amiri A, Pourhanifeh MH, Mirzaei HR, Nahand JS, Moghoofei M, Sahebnasagh R, Mirzaei H, Hamblin MR. Exosomes and lung cancer: roles in pathophysiology, diagnosis and therapeutic applications. Curr Med Chem. 2021;28(2):308\u201328.","journal-title":"Curr Med Chem"},{"key":"2753_CR37","volume":"8","author":"Q Bao","year":"2021","unstructured":"Bao Q, Huang Q, Chen Y, Wang Q, Sang R, Wang L, Xie Y, Chen W. Tumor-derived extracellular vesicles regulate cancer progression in the tumor microenvironment. Front Mol Biosci. 2021;8: 796385.","journal-title":"Front Mol Biosci"},{"key":"2753_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2017.12.012","volume":"116","author":"S Cui","year":"2018","unstructured":"Cui S, Cheng Z, Qin W, Jiang L. Exosomes as a liquid biopsy for lung cancer. Lung Cancer. 2018;116:46\u201354.","journal-title":"Lung Cancer"},{"issue":"1","key":"2753_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-021-01411-w","volume":"20","author":"C Jiang","year":"2021","unstructured":"Jiang C, Zhang N, Hu X, Wang H. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer. 2021;20(1):117.","journal-title":"Mol Cancer"},{"key":"2753_CR40","doi-asserted-by":"crossref","unstructured":"Keogh A, Finn S, Radonic T. Emerging biomarkers and the changing landscape of small cell lung cancer. Cancers (Basel). 2022;14(15):3772.","DOI":"10.3390\/cancers14153772"},{"key":"2753_CR41","doi-asserted-by":"crossref","unstructured":"Sand\u00faa A, Alegre E, Gonz\u00e1lez \u00c1. Exosomes in lung cancer: actors and heralds of tumor development. Cancers (Basel). 2021;13(17):4330.","DOI":"10.3390\/cancers13174330"},{"key":"2753_CR42","doi-asserted-by":"crossref","unstructured":"Batista IA, Melo SA. Exosomes and the future of immunotherapy in pancreatic cancer. Int J Mol Sci. 2019;20(3):567.","DOI":"10.3390\/ijms20030567"},{"key":"2753_CR43","doi-asserted-by":"crossref","unstructured":"Fu M, Gu J, Jiang P, Qian H, Xu W, Zhang X. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol Cancer. 2019;18(1):41.","DOI":"10.1186\/s12943-019-1001-7"},{"key":"2753_CR44","doi-asserted-by":"crossref","unstructured":"Huang S, Dong M, Chen Q. Tumor-derived exosomes and their role in breast cancer metastasis. Int J Mol Sci.  2022;23(22):13993.","DOI":"10.3390\/ijms232213993"},{"issue":"10","key":"2753_CR45","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1002\/jcp.29668","volume":"235","author":"N Jabbari","year":"2020","unstructured":"Jabbari N, Akbariazar E, Feqhhi M, Rahbarghazi R, Rezaie J. Breast cancer-derived exosomes: Tumor progression and therapeutic agents. J Cell Physiol. 2020;235(10):6345\u201356.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2753_CR46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-019-0806-6","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12(1):133.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2753_CR47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","volume":"13","author":"S Zhao","year":"2020","unstructured":"Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu Y, Zhang Z, Cai S, Xu Y, Li X, He X, Zhong X, Li G, Chen Z, Li D. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2020;13(1):156.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2753_CR48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12943-022-01556-2","volume":"21","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhu L, Song J, Wang G, Li P, Li W, Luo P, Sun X, Wu J, Liu Y, Zhu S, Zhang Y. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86.","journal-title":"Mol Cancer"},{"key":"2753_CR49","volume":"268","author":"W Zhou","year":"2021","unstructured":"Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, Zhang Y, Liu P, Zhang Y, Li C, Chu Y, Sun T, Jiang C. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268: 120546.","journal-title":"Biomaterials"},{"key":"2753_CR50","doi-asserted-by":"crossref","unstructured":"Hao Q, Wu Y, Wu Y, Wang P, Vadgama JV. Tumor-derived exosomes in tumor-induced immune suppression. Int J Mol Sci. 2022;23(3):1461.","DOI":"10.3390\/ijms23031461"},{"issue":"1","key":"2753_CR51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12935-021-01990-0","volume":"21","author":"R Qi","year":"2021","unstructured":"Qi R, Zhao Y, Guo Q, Mi X, Cheng M, Hou W, Zheng H, Hua B. Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers. Cancer Cell Int. 2021;21(1):333.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2753_CR52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-020-00987-y","volume":"13","author":"L Zhu","year":"2020","unstructured":"Zhu L, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, Hu BY, Qin W, Zou TT, Fu Y, Shen XT, Zhu WW, Geng Y, Lu L, Jia HL, Qin LX, Dong QZ. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13(1):152.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2753_CR53","first-page":"2226","volume":"12","author":"J Cheng","year":"2022","unstructured":"Cheng J, Wang X, Yuan X, Liu G, Chu Q. Emerging roles of exosome-derived biomarkers in cancer theranostics: messages from novel protein targets. Am J Cancer Res. 2022;12(5):2226\u201348.","journal-title":"Am J Cancer Res"},{"key":"2753_CR54","doi-asserted-by":"crossref","unstructured":"Najaflou M, Shahgolzari M, Khosroushahi AY, Fiering S. Tumor-derived extracellular vesicles in cancer immunoediting and their potential as oncoimmunotherapeutics. Cancers (Basel). 2022;15(1):82.","DOI":"10.3390\/cancers15010082"},{"key":"2753_CR55","doi-asserted-by":"crossref","unstructured":"Tartarone A, Lerose R, Tartarone M, Aieta M. potential role of tumor-derived exosomes in non-small-cell lung cancer in the era of immunotherapy. Life (Basel). 2022;12(12):2104.","DOI":"10.3390\/life12122104"},{"issue":"1","key":"2753_CR56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"key":"2753_CR57","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fonc.2020.00760","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, Wang S, Wen T, Hou K, Shao X, Liu Y, Qu X. Anti-PD-1 Therapy response predicted by the combination of exosomal PD-L1 and CD28. Front Oncol. 2020;10:760.","journal-title":"Front Oncol"},{"issue":"6","key":"2753_CR58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","volume":"31","author":"G Abril-Rodriguez","year":"2017","unstructured":"Abril-Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848-848.e841.","journal-title":"Cancer Cell"},{"key":"2753_CR59","doi-asserted-by":"crossref","first-page":"8839978","DOI":"10.1155\/2021\/8839978","volume":"2021","author":"S Ayala-Mar","year":"2021","unstructured":"Ayala-Mar S, Donoso-Quezada J, Gonz\u00e1lez-Valdez J. Clinical implications of exosomal pd-l1 in cancer immunotherapy. J Immunol Res. 2021;2021:8839978.","journal-title":"J Immunol Res"},{"key":"2753_CR60","doi-asserted-by":"crossref","unstructured":"Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC and Sozzi G. Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study. Clin Cancer Res. 2019; 25(7):2166\u20132173, 2019.","DOI":"10.1158\/1078-0432.CCR-18-1981"},{"issue":"9","key":"2753_CR61","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391.","journal-title":"J Clin Invest"},{"issue":"1","key":"2753_CR62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","volume":"41","author":"D de Miguel-Perez","year":"2022","unstructured":"de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41(1):186.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2753_CR63","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.2018.9","volume":"118","author":"M Del Re","year":"2018","unstructured":"Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, Restante G, Arrigoni E, Caparello C, Bianco MG, Crucitta S, Petrini I, Vasile E, Falcone A, Danesi R. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. Br J Cancer. 2018;118(6):820\u20134.","journal-title":"Br J Cancer"},{"issue":"1","key":"2753_CR64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-020-02306-y","volume":"18","author":"A Raza","year":"2020","unstructured":"Raza A, Merhi M, Inchakalody VP, Krishnankutty R, Relecom A, Uddin S, Dermime S. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. J Transl Med. 2020;18(1):140.","journal-title":"J Transl Med"},{"issue":"1","key":"2753_CR65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-019-0772-z","volume":"12","author":"X Tian","year":"2019","unstructured":"Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12(1):84.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2753_CR66","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jtho.2016.05.034","volume":"11","author":"B Sandfeld-Paulsen","year":"2016","unstructured":"Sandfeld-Paulsen B, Jakobsen KR, B\u00e6k R, Folkersen BH, Rasmussen TR, Meldgaard P, Varming K, J\u00f8rgensen MM, Sorensen BS. Exosomal proteins as diagnostic biomarkers in lung cancer. J Thorac Oncol. 2016;11(10):1701\u201310.","journal-title":"J Thorac Oncol"},{"key":"2753_CR67","doi-asserted-by":"crossref","unstructured":"Lin Q, Xie D, Pan L, Lou Y, Shi M. Urinary exosomal long noncoding RNAs serve as biomarkers for early detection of non-small cell lung cancer. Biosci Rep. 2021;41(10):BSR20210908.","DOI":"10.1042\/BSR20210908"},{"issue":"1","key":"2753_CR68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.29417","volume":"138","author":"P Penfornis","year":"2016","unstructured":"Penfornis P, Vallabhaneni KC, Whitt J, Pochampally R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int J Cancer. 2016;138(1):14\u201321.","journal-title":"Int J Cancer"},{"issue":"1","key":"2753_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-022-01671-0","volume":"21","author":"QF Han","year":"2022","unstructured":"Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21(1):207.","journal-title":"Mol Cancer"},{"issue":"1","key":"2753_CR70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7150\/thno.21945","volume":"8","author":"C He","year":"2018","unstructured":"He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018;8(1):237\u201355.","journal-title":"Theranostics"},{"key":"2753_CR71","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2022;367(6478):aau6977."},{"issue":"5867","key":"2753_CR72","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","volume":"319","author":"K Trajkovic","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Br\u00fcgger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244\u20137.","journal-title":"Science"},{"key":"2753_CR73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5772\/61186","volume":"4","author":"KJ McKelvey","year":"2015","unstructured":"McKelvey KJ, Powell KL, Ashton AW, Morris JM, McCracken SA. Exosomes: mechanisms of uptake. J Circ Biomark. 2015;4:7.","journal-title":"J Circ Biomark"},{"key":"2753_CR74","doi-asserted-by":"crossref","unstructured":"Kavya AN, Subramanian S, Ramakrishna S. Therapeutic applications of exosomes in various diseases: a review. Biomater Adv. 2022;134:12579.","DOI":"10.1016\/j.msec.2021.112579"},{"key":"2753_CR75","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","volume":"88","author":"DM Pegtel","year":"2019","unstructured":"Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487\u2013514.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2753_CR76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.","journal-title":"Cell Commun Signal"},{"key":"2753_CR77","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221: 107753.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"2753_CR78","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605\u201318.","journal-title":"Trends Cancer"},{"issue":"3","key":"2753_CR79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mc.23378","volume":"61","author":"MN Rizwan","year":"2022","unstructured":"Rizwan MN, Ma Y, Nenkov M, Jin L, Schr\u00f6der DC, Westermann M, Ga\u00dfler N, Chen Y. Tumor-derived exosomes: key players in non-small cell lung cancer metastasis and their implication for targeted therapy. Mol Carcinog. 2022;61(3):269\u201380.","journal-title":"Mol Carcinog"},{"key":"2753_CR80","doi-asserted-by":"crossref","unstructured":"Blackwell RH, Foreman KE, Gupta GN. The role of cancer-derived exosomes in tumorigenicity & epithelial-to-mesenchymal transition. Cancers (Basel). 2017;9(8):105.","DOI":"10.3390\/cancers9080105"},{"issue":"4","key":"2753_CR81","first-page":"5860","volume":"17","author":"J Peng","year":"2018","unstructured":"Peng J, Yu Z, Xue L, Wang J, Li J, Liu D, Yang Q, Lin Y. The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells. Mol Med Rep. 2018;17(4):5860\u20138.","journal-title":"Mol Med Rep"},{"key":"2753_CR82","doi-asserted-by":"crossref","unstructured":"Pritchard A, Tousif S, Wang Y, Hough K, Khan S, Strenkowski J, Chacko BK, Darley-Usmar VM, Deshane JS. Lung tumor cell-derived exosomes promote M2 macrophage polarization. Cells. 2020;9(5):1303.","DOI":"10.3390\/cells9051303"},{"issue":"2","key":"2753_CR83","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ymthe.2017.11.016","volume":"26","author":"YL Hsu","year":"2018","unstructured":"Hsu YL, Hung JY, Chang WA, Jian SF, Lin YS, Pan YC, Wu CY, Kuo PL. Hypoxic lung-cancer-derived extracellular vesicle MicroRNA-103a increases the oncogenic effects of macrophages by Targeting PTEN. Mol Ther. 2018;26(2):568\u201381.","journal-title":"Mol Ther"},{"issue":"1","key":"2753_CR84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-019-1027-0","volume":"38","author":"W Ren","year":"2019","unstructured":"Ren W, Hou J, Yang C, Wang H, Wu S, Wu Y, Zhao X, Lu C. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. J Exp Clin Cancer Res. 2019;38(1):62.","journal-title":"J Exp Clin Cancer Res"},{"key":"2753_CR85","first-page":"963689722110699","volume":"31","author":"S Zhou","year":"2022","unstructured":"Zhou S, Lan Y, Li Y, Li Z, Pu J, Wei L. Hypoxic tumor-derived exosomes induce M2 macrophage polarization via PKM2\/AMPK to promote lung cancer progression. Cell Transplant. 2022;31:9636897221106998.","journal-title":"Cell Transplant"},{"issue":"12","key":"2753_CR86","first-page":"835","volume":"25","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Guo L, Guo S. Exosomal miR-10b promotes invasion and epithelial-mesenchymal transformation of lung adenocarcinoma A549 cells by regulating macrophage M2 polarization. Zhongguo Fei Ai Za Zhi. 2022;25(12):835\u201342.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"10","key":"2753_CR87","doi-asserted-by":"crossref","first-page":"14456","DOI":"10.18632\/aging.103556","volume":"13","author":"H Wang","year":"2021","unstructured":"Wang H, Huang H, Wang L, Liu Y, Wang M, Zhao S, Lu G, Kang X. Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer. Aging (Albany NY). 2021;13(10):14456\u201368.","journal-title":"Aging (Albany NY)"},{"key":"2753_CR88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molimm.2021.10.002","volume":"140","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Wang K, Lu X, Wang Y, Chen J. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1\/ miR-142-5p\/ PD-L1 axis. Mol Immunol. 2021;140:47\u201358.","journal-title":"Mol Immunol"},{"issue":"7","key":"2753_CR89","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1042\/CS20200039","volume":"134","author":"J Fan","year":"2020","unstructured":"Fan J, Xu G, Chang Z, Zhu L, Yao J. miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2\/STAT3 pathway. Clin Sci (Lond). 2020;134(7):807\u201325.","journal-title":"Clin Sci (Lond)"},{"issue":"40","key":"2753_CR90","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41388-020-01406-9","volume":"39","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li F, Tang Y, Ren Q, Xiao B, Wan Y, Jiang S. miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells. Oncogene. 2020;39(40):6354\u201369.","journal-title":"Oncogene"},{"key":"2753_CR91","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.2147\/OTT.S256378","volume":"13","author":"JH Zhou","year":"2020","unstructured":"Zhou JH, Yao ZX, Zheng Z, Yang J, Wang R, Fu SJ, Pan XF, Liu ZH, Wu K. G-MDSCs-derived exosomal miRNA-143-3p promotes proliferation via targeting of ITM2B in lung cancer. Onco Targets Ther. 2020;13:9701\u201319.","journal-title":"Onco Targets Ther"},{"key":"2753_CR92","doi-asserted-by":"crossref","first-page":"10693","DOI":"10.2147\/OTT.S256669","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to Inhibit Dendritic Cell Phagocytosis inflammatory response, costimulatory molecule expression and promote dendritic cell autophagy via AKT\/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2753_CR93","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7150\/ijbs.38414","volume":"16","author":"C Wang","year":"2020","unstructured":"Wang C, Huang X, Wu Y, Wang J, Li F, Guo G. Tumor cell-associated exosomes robustly elicit anti-tumor immune responses through modulating dendritic cell vaccines in lung tumor. Int J Biol Sci. 2020;16(4):633\u201343.","journal-title":"Int J Biol Sci"},{"issue":"13","key":"2753_CR94","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41388-020-1182-y","volume":"39","author":"S Yu","year":"2020","unstructured":"Yu S, Sha H, Qin X, Chen Y, Li X, Shi M, Feng J. EGFR E746\u2013A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. 2020;39(13):2643\u201357.","journal-title":"Oncogene"},{"issue":"1","key":"2753_CR95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41419-020-2230-9","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Zhao X, Wang Y, Ren F, Sun D, Yan Y, Kong X, Bu J, Liu M, Xu S. circRNA-002178 act as a ceRNA to promote PDL1\/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11(1):32.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2753_CR96","first-page":"1","volume":"51","author":"DH Kim","year":"2019","unstructured":"Kim DH, Kim H, Choi YJ, Kim SY, Lee JE, Sung KJ, Sung YH, Pack CG, Jung MK, Han B, Kim K, Kim WS, Nam SJ, Choi CM, Yun M, Lee JC, Rho JK. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51(8):1\u201313.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2753_CR97","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","volume":"20","author":"SW Chen","year":"2021","unstructured":"Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Long X, Lin K, Lu F, Xu JJ, Wu YB. Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC. Mol Cancer. 2021;20(1):144.","journal-title":"Mol Cancer"},{"issue":"2","key":"2753_CR98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13258-022-01306-0","volume":"45","author":"F Gao","year":"2023","unstructured":"Gao F, Han J, Jia L, He J, Wang Y, Chen M, Liu X, He X. MiR-30c facilitates natural killer cell cytotoxicity to lung cancer through targeting GALNT7. Genes Genomics. 2023;45(2):247\u201360.","journal-title":"Genes Genomics"},{"issue":"Suppl 1","key":"2753_CR99","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.21037\/tcr.2017.02.13","volume":"6","author":"TL Whiteside","year":"2017","unstructured":"Whiteside TL. The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT). Transl Cancer Res. 2017;6(Suppl 1):S90-s92.","journal-title":"Transl Cancer Res"},{"issue":"31","key":"2753_CR100","doi-asserted-by":"crossref","first-page":"E2110","DOI":"10.1073\/pnas.1209414109","volume":"109","author":"M Fabbri","year":"2012","unstructured":"Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109(31):E2110-2116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2753_CR101","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062968","volume":"5","author":"G Berchem","year":"2016","unstructured":"Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, Nanbakhsh A, Moussay E, Mami-Chouaib F, Janji B, Chouaib S. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-\u03b2 and miR23a transfer. Oncoimmunology. 2016;5(4): e1062968.","journal-title":"Oncoimmunology"},{"key":"2753_CR102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcancer.2014.02.010","volume":"28","author":"L Mincheva-Nilsson","year":"2014","unstructured":"Mincheva-Nilsson L, Baranov V. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol. 2014;28:24\u201330.","journal-title":"Semin Cancer Biol"},{"key":"2753_CR103","doi-asserted-by":"crossref","unstructured":"Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science. 2015;348(6230):136-9.","DOI":"10.1126\/science.1258867"},{"issue":"1","key":"2753_CR104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST20120265","volume":"41","author":"TL Whiteside","year":"2013","unstructured":"Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245\u201351.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"2753_CR105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"2753_CR106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semcdb.2018.02.015","volume":"86","author":"CE Bryant","year":"2019","unstructured":"Bryant CE, Sutherland S, Kong B, Papadimitrious MS, Fromm PD, Hart DNJ. Dendritic cells as cancer therapeutics. Semin Cell Dev Biol. 2019;86:77\u201388.","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"2753_CR107","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1172\/JCI81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Andr\u00e9 F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Invest. 2016;126(4):1224\u201332.","journal-title":"J Clin Invest"},{"issue":"2","key":"2753_CR108","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.20812","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L, Zhang L, Wu Q, Chang X, Yu X, Liu T. Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget. 2018;9(2):2887\u201394.","journal-title":"Oncotarget"},{"issue":"2","key":"2753_CR109","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.intimp.2015.02.010","volume":"25","author":"P Zhao","year":"2015","unstructured":"Zhao P, Bu X, Wei X, Sun W, Xie X, Li C, Guo Q, Zhu D, Wei X, Gao D. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 2015;25(2):450\u20136.","journal-title":"Int Immunopharmacol"},{"key":"2753_CR110","volume":"11","author":"D Stevens","year":"2020","unstructured":"Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K. Dendritic Cell-Based Immunotherapy in Lung Cancer. Front Immunol. 2020;11: 620374.","journal-title":"Front Immunol"},{"issue":"5","key":"2753_CR111","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/07357907.2013.789905","volume":"31","author":"SH Huang","year":"2013","unstructured":"Huang SH, Li Y, Zhang J, Rong J, Ye S. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest. 2013;31(5):330\u20135.","journal-title":"Cancer Invest"},{"key":"2753_CR112","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","volume":"353","author":"J Li","year":"2023","unstructured":"Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Control Release. 2023;353:423\u201333.","journal-title":"J Control Release"},{"issue":"3","key":"2753_CR113","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"3","key":"2753_CR114","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"2753_CR115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","volume":"1224","author":"M Dysthe","year":"2020","unstructured":"Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:117\u201340.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"2753_CR116","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008371","volume":"4","author":"K Ridder","year":"2015","unstructured":"Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, S\u00fcltmann H, Altevogt P, Umansky V, Momma S. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology. 2015;4(6): e1008371.","journal-title":"Oncoimmunology"},{"issue":"11","key":"2753_CR117","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.24249","volume":"124","author":"X Xiang","year":"2009","unstructured":"Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, Grizzle WE, Mobley J, Zhang HG. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621\u201333.","journal-title":"Int J Cancer"},{"issue":"2","key":"2753_CR118","first-page":"457","volume":"120","author":"F Chalmin","year":"2010","unstructured":"Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, R\u00e9b\u00e9 C, Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457\u201371.","journal-title":"J Clin Invest"},{"key":"2753_CR119","doi-asserted-by":"crossref","unstructured":"Mignot G, Chalmin F, Ladoire S, R\u00e9b\u00e9 C and Ghiringhelli F. Tumor exosome-mediated MDSC activation. Am J Pathol. 2011; 178(3): 1403\u20131404; author reply 1404\u20131405.","DOI":"10.1016\/j.ajpath.2010.11.078"},{"issue":"5","key":"2753_CR120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1189\/jlb.0913485","volume":"95","author":"L Garzetti","year":"2014","unstructured":"Garzetti L, Menon R, Finardi A, Bergami A, Sica A, Martino G, Comi G, Verderio C, Farina C, Furlan R. Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs. J Leukoc Biol. 2014;95(5):817\u201325.","journal-title":"J Leukoc Biol"},{"key":"2753_CR121","volume":"8","author":"Q Chen","year":"2021","unstructured":"Chen Q, Li Y, Gao W, Chen L, Xu W, Zhu X. Exosome-mediated crosstalk between tumor and tumor-associated macrophages. Front Mol Biosci. 2021;8: 764222.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"2753_CR122","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.21037\/tlcr-20-1241","volume":"10","author":"SS Sedighzadeh","year":"2021","unstructured":"Sedighzadeh SS, Khoshbin AP, Razi S, Keshavarz-Fathi M, Rezaei N. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Transl Lung Cancer Res. 2021;10(4):1889\u2013916.","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"2753_CR123","first-page":"1167","volume":"37","author":"Z Li","year":"2022","unstructured":"Li Z, Wang YJ, Zhou J, Umakoshi M, Goto A. The prognostic role of M2 tumor-associated macrophages in non-small-cell lung cancer. Histol Histopathol. 2022;37(12):1167\u201375.","journal-title":"Histol Histopathol"},{"key":"2753_CR124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2017.01.003","volume":"106","author":"T Iriki","year":"2017","unstructured":"Iriki T, Ohnishi K, Fujiwara Y, Horlad H, Saito Y, Pan C, Ikeda K, Mori T, Suzuki M, Ichiyasu H, Kohrogi H, Takeya M, Komohara Y. The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer. 2017;(106):22\u201332.","journal-title":"Lung Cancer"},{"issue":"19","key":"2753_CR125","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1158\/0008-5472.CAN-18-0562","volume":"78","author":"S Roy","year":"2018","unstructured":"Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH, Batra SK, Datta K. Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions. Cancer Res. 2018;78(19):5600\u201317.","journal-title":"Cancer Res"},{"issue":"4","key":"2753_CR126","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ijc.32151","volume":"145","author":"L Yang","year":"2019","unstructured":"Yang L, Dong Y, Li Y, Wang D, Liu S, Wang D, Gao Q, Ji S, Chen X, Lei Q, Jiang W, Wang L, Zhang B, Yu JJ, Zhang Y. IL-10 derived from M2 macrophage promotes cancer stemness via JAK1\/STAT1\/NF-\u03baB\/Notch1 pathway in non-small cell lung cancer. Int J Cancer. 2019;145(4):1099\u2013110.","journal-title":"Int J Cancer"},{"issue":"10","key":"2753_CR127","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/acs.jproteome.5b00770","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Chen X, Pan Q, Wang Y, Su S, Jiang C, Li Y, Xu N, Wu L, Lou X, Liu S. A comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor-associated macrophages. J Proteome Res. 2015;14(10):4319\u201331.","journal-title":"J Proteome Res"},{"key":"2753_CR128","doi-asserted-by":"crossref","first-page":"1078029","DOI":"10.3389\/fonc.2023.1078029","volume":"13","author":"O Kovaleva","year":"2023","unstructured":"Kovaleva O, Sorokin M, Egorova A, Petrenko A, Shelekhova K, Gratchev A. Macrophage - tumor cell interaction beyond cytokines. Front Oncol. 2023;(13):1078029.","journal-title":"Front Oncol"},{"issue":"4","key":"2753_CR129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"},{"key":"2753_CR130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2018.05.002","volume":"199","author":"Y Ning","year":"2018","unstructured":"Ning Y, Shen K, Wu Q, Sun X, Bai Y, Xie Y, Pan J, Qi C. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett. 2018;199:36\u201343.","journal-title":"Immunol Lett"},{"key":"2753_CR131","doi-asserted-by":"crossref","first-page":"20254","DOI":"10.1038\/srep20254","volume":"6","author":"L Muller","year":"2016","unstructured":"Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 2016;6:20254.","journal-title":"Sci Rep"},{"issue":"2","key":"2753_CR132","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4049\/jimmunol.1003884","volume":"187","author":"A Clayton","year":"2011","unstructured":"Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011;187(2):676\u201383.","journal-title":"J Immunol"},{"issue":"1","key":"2753_CR133","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","volume":"18","author":"F Xie","year":"2019","unstructured":"Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. 2019;18(1):146.","journal-title":"Mol Cancer"},{"issue":"2","key":"2753_CR134","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Blelloch R. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414-427.e413.","journal-title":"Cell"},{"issue":"10","key":"2753_CR135","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/cr.2014.121","volume":"24","author":"Y Yin","year":"2014","unstructured":"Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Chen X, Zhang W, Yokoyama S, Wang C, Li L, Li L, Hou D, Dong L, Xu T, Hiroi T, Yang F, Ji H, Zhang J, Zen K, Zhang CY. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164\u201380.","journal-title":"Cell Res"},{"issue":"7","key":"2753_CR136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011469","volume":"5","author":"M Szajnik","year":"2010","unstructured":"Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7): e11469.","journal-title":"PLoS One"},{"issue":"9","key":"2753_CR137","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo Jr","year":"2021","unstructured":"Galbo PM Jr, Zang X, Zheng D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis prognosi, and immunotherapy resistence. Clin Cancer Res. 2021;27(9):2636\u201347.","journal-title":"Clin Cancer Res"},{"key":"2753_CR138","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.009","volume":"514","author":"H Zhang","year":"2021","unstructured":"Zhang H, Jiang H, Zhu L, Li J, Ma S. Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives. Cancer Lett. 2021;(514):38\u201347.","journal-title":"Cancer Lett"},{"issue":"1","key":"2753_CR139","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10020-021-00402-3","volume":"27","author":"YF Chen","year":"2021","unstructured":"Chen YF, Yu ZL, Lv MY, Cai ZR, Zou YF, Lan P, Wu XJ, Gao F. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis. Mol Med. 2021;27(1):139.","journal-title":"Mol Med"},{"issue":"11","key":"2753_CR140","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1021\/acsbiomaterials.1c00611","volume":"7","author":"M Zhou","year":"2021","unstructured":"Zhou M, Wang S, Liu D, Zhou J. LINC01915 Facilitates the Conversion of Normal Fibroblasts into Cancer-Associated Fibroblasts Induced by Colorectal Cancer-Derived Extracellular Vesicles through the miR-92a-3p\/KLF4\/CH25H Axis. ACS Biomater Sci Eng. 2021;7(11):5255\u201368.","journal-title":"ACS Biomater Sci Eng"},{"issue":"6","key":"2753_CR141","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, Garc\u00eda-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816\u201326.","journal-title":"Nat Cell Biol"},{"key":"2753_CR142","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.actbio.2021.09.003","volume":"135","author":"S Hu","year":"2021","unstructured":"Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, Zhang B, Shi G, Zhang Y, Zhang Y, Huang A, Kuang Y, Cheng P. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021;(135):567\u201381.","journal-title":"Acta Biomater"},{"key":"2753_CR143","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2017.08.009","volume":"182","author":"M Singh","year":"2018","unstructured":"Singh M, Yelle N, Venugopal C, Singh SK. EMT: Mechanisms and therapeutic implications. Pharmacol Ther. 2018;(182):80\u201394.","journal-title":"Pharmacol Ther"},{"key":"2753_CR144","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108984","volume":"710","author":"J Jayachandran","year":"2021","unstructured":"Jayachandran J, Srinivasan H, Mani KP. Molecular mechanism involved in epithelial to mesenchymal transition. Arch Biochem Biophys. 2021;(710):108984.","journal-title":"Arch Biochem Biophys"},{"issue":"34","key":"2753_CR145","doi-asserted-by":"crossref","first-page":"54852","DOI":"10.18632\/oncotarget.10243","volume":"7","author":"MA Rahman","year":"2016","unstructured":"Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 2016;7(34):54852\u201366.","journal-title":"Oncotarget"},{"issue":"1","key":"2753_CR146","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12864-018-5143-6","volume":"19","author":"YT Tang","year":"2018","unstructured":"Tang YT, Huang YY, Li JH, Qin SH, Xu Y, An TX, Liu CC, Wang Q, Zheng L. Alterations in exosomal miRNA profile upon epithelial-mesenchymal transition in human lung cancer cell lines. BMC Genomics. 2018;19(1):802.","journal-title":"BMC Genomics"},{"issue":"2","key":"2753_CR147","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.yexcr.2019.03.035","volume":"379","author":"S He","year":"2019","unstructured":"He S, Li Z, Yu Y, Zeng Q, Cheng Y, Ji W, Xia W, Lu S. Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. Exp Cell Res. 2019;379(2):203\u201313.","journal-title":"Exp Cell Res"},{"key":"2753_CR148","doi-asserted-by":"crossref","unstructured":"Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, Li G, Tang J, Xiang J. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18(1):1\u201315.","DOI":"10.1186\/s12943-019-0959-5"},{"key":"2753_CR149","volume":"73","author":"F Yang","year":"2020","unstructured":"Yang F, Yan Y, Yang Y, Hong X, Wang M, Yang Z, Liu B, Ye L. MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN\/PI3K\/AKT pathway. Cell Signal. 2020;(73):109675.","journal-title":"Cell Signal"},{"issue":"2","key":"2753_CR150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbrc.2016.07.124","volume":"478","author":"J Kim","year":"2016","unstructured":"Kim J, Kim TY, Lee MS, Mun JY, Ihm C, Kim SA. Exosome cargo reflects TGF-\u03b21-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016;478(2):643\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2753_CR151","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11912-008-0043-6","volume":"10","author":"RK Goudar","year":"2008","unstructured":"Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep. 2008;10(4):277\u201382.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2753_CR152","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"key":"2753_CR153","volume":"240","author":"MT Bu","year":"2022","unstructured":"Bu MT, Chandrasekhar P, Ding L, Hugo W. The roles of TGF-\u03b2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther. 2022;(240):108211.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2753_CR154","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-019-0982-6","volume":"18","author":"W Meng","year":"2019","unstructured":"Meng W, Hao Y, He C, Li L, Zhu G. Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 2019;18(1):57.","journal-title":"Mol Cancer"},{"issue":"42","key":"2753_CR155","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.2174\/0929867325666180904114455","volume":"26","author":"G Selvaraj","year":"2019","unstructured":"Selvaraj G, Kaliamurthi S, Lin S, Gu K, Wei DQ. Prognostic impact of tissue inhibitor of metalloproteinase-1 in non- small cell lung cancer: systematic review and meta-analysis. Curr Med Chem. 2019;26(42):7694\u2013713.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2753_CR156","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2015.10.011","volume":"370","author":"Y Liu","year":"2016","unstructured":"Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, Shi L, Lu X, Xu W, Lu L, Qin Y, Xiang Q, Liu Q. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016;370(1):125\u201335.","journal-title":"Cancer Lett"},{"issue":"3","key":"2753_CR157","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1039\/C9LC00958B","volume":"20","author":"K Jeong","year":"2020","unstructured":"Jeong K, Yu YJ, You JY, Rhee WJ, Kim JA. Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model. Lab Chip. 2020;20(3):548\u201357.","journal-title":"Lab Chip"},{"key":"2753_CR158","doi-asserted-by":"crossref","unstructured":"Hsu MT, Wang YK, Tseng YJ. Exosomal proteins and lipids as potential biomarkers for lung cancer diagnosis, prognosis, and treatment. Cancers (Basel). 2022;14(3):732.","DOI":"10.3390\/cancers14030732"},{"issue":"10","key":"2753_CR159","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.molonc.2016.10.003","volume":"10","author":"B Sandfeld-Paulsen","year":"2016","unstructured":"Sandfeld-Paulsen B, Aggerholm-Pedersen N, B\u00e6k R, Jakobsen KR, Meldgaard P, Folkersen BH, Rasmussen TR, Varming K, J\u00f8rgensen MM, Sorensen BS. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol. 2016;10(10):1595\u2013602.","journal-title":"Mol Oncol"},{"issue":"2","key":"2753_CR160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/ijms17020175","volume":"17","author":"C Ciardiello","year":"2016","unstructured":"Ciardiello C, Cavallini L, Spinelli C, Yang J, Reis-Sobreiro M, de Candia P, Minciacchi VR, Di Vizio D. Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer. Int J Mol Sci. 2016;17(2):175.","journal-title":"Int J Mol Sci"},{"issue":"3\u20134","key":"2753_CR161","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/prca.201400114","volume":"9","author":"S Boukouris","year":"2015","unstructured":"Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015;9(3\u20134):358\u201367.","journal-title":"Proteomics Clin Appl"},{"key":"2753_CR162","doi-asserted-by":"crossref","unstructured":"Choi ES, Faruque HA, Kim JH, Kim KJ, Choi JE, Kim BA, Kim B, Kim YJ, Woo MH, Park JY, Hur K, Lee MY, Kim DS, Lee SY, Kim E. CD5L as an extracellular vesicle-derived biomarker for liquid biopsy of lung cancer. Diagnostics (Basel). 2021;11(4):620.","DOI":"10.3390\/diagnostics11040620"},{"issue":"3","key":"2753_CR163","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2018.02.114","volume":"498","author":"J Gao","year":"2018","unstructured":"Gao J, Qiu X, Li X, Fan H, Zhang F, Lv T, Song Y. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. Biochem Biophys Res Commun. 2018;498(3):409\u201315.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2753_CR164","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/cas.13581","volume":"109","author":"N Wang","year":"2018","unstructured":"Wang N, Song X, Liu L, Niu L, Wang X, Song X, Xie L. Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer. Cancer Sci. 2018;109(5):1701\u20139.","journal-title":"Cancer Sci"},{"issue":"15","key":"2753_CR165","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.7150\/jca.30425","volume":"10","author":"F Wu","year":"2019","unstructured":"Wu F, Yin Z, Yang L, Fan J, Xu J, Jin Y, Yu J, Zhang D, Yang G. Smoking induced extracellular vesicles release and their distinct properties in non-small cell lung cancer. J Cancer. 2019;10(15):3435\u201343.","journal-title":"J Cancer"},{"issue":"12","key":"2753_CR166","first-page":"969","volume":"68","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Kamada H, Kanasaki S, Maeda Y, Nagano K, Abe Y, Inoue M, Yoshioka Y, Tsutsumi Y, Katayama S, Inoue M, Tsunoda S. Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. Pharmazie. 2013;68(12):969\u201373.","journal-title":"Pharmazie"},{"key":"2753_CR167","doi-asserted-by":"crossref","unstructured":"Patel G, Agnihotri TG, Gitte M, Shinde T, Gomte SS, Goswami R, Jain A. Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer. Cell Oncol (Dordr). 2023:1\u201321.","DOI":"10.1007\/s13402-023-00810-z"},{"issue":"6","key":"2753_CR168","volume":"53","author":"C Hu","year":"2020","unstructured":"Hu C, Meiners S, Lukas C, Stathopoulos GT, Chen J. Role of exosomal microRNAs in lung cancer biology and clinical applications. Cell Prolif. 2020;53(6): e12828.","journal-title":"Cell Prolif"},{"issue":"39","key":"2753_CR169","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.2174\/1381612823666170714150118","volume":"23","author":"X Du","year":"2018","unstructured":"Du X, Zhang J, Wang J, Lin X, Ding F. Role of miRNA in lung cancer-potential biomarkers and therapies. Curr Pharm Des. 2018;23(39):5997\u20136010.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"2753_CR170","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41419-022-05420-5","volume":"13","author":"RM Chang","year":"2022","unstructured":"Chang RM, Fu Y, Zeng J, Zhu XY, Gao Y. Cancer-derived exosomal miR-197-3p confers angiogenesis via targeting TIMP2\/3 in lung adenocarcinoma metastasis. Cell Death Dis. 2022;13(12):1032.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2753_CR171","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.21037\/tcr-20-2815","volume":"10","author":"E Dur\u00e9ndez-S\u00e1ez","year":"2021","unstructured":"Dur\u00e9ndez-S\u00e1ez E, Torres-Martinez S, Calabuig-Fari\u00f1as S, Meri-Abad M, Ferrero-Gimeno M, Camps C. Exosomal microRNAs in non-small cell lung cancer. Transl Cancer Res. 2021;10(6):3128\u201339.","journal-title":"Transl Cancer Res"},{"issue":"17","key":"2753_CR172","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-17-0577","volume":"23","author":"X Jin","year":"2017","unstructured":"Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, Su M, Pan H, Shen L, Xie D, Xie C. Evaluation of tumor-derived exosomal mirna as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2753_CR173","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1111\/1759-7714.13644","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Jiang X, Li J, Wang J, Binang H, Shi S, Duan W, Zhao Y, Zhang Y. Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer. Thorac Cancer. 2020;11(12):3436\u201347.","journal-title":"Thorac Cancer"},{"issue":"9","key":"2753_CR174","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/JTO.0b013e318299ac32","volume":"8","author":"R Cazzoli","year":"2013","unstructured":"Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8(9):1156\u201362.","journal-title":"J Thorac Oncol"},{"key":"2753_CR175","doi-asserted-by":"crossref","unstructured":"Lin J, Wang Y, Zou YQ, Chen X, Huang B, Liu J, Xu YM, Li J, Zhang J, Yang WM, Min QH, Sun F,  Li SQ, Gao QF, Wang XZ. Differential miRNA expression in pleural effusions derived from extracellular vesicles of patients with lung cancer, pulmonary tuberculosis, or pneumonia. Tumour Biol. 2016;(37):15835\u201345.","DOI":"10.1007\/s13277-016-5410-6"},{"issue":"12","key":"2753_CR176","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.21873\/anticanres.13039","volume":"38","author":"H Tamiya","year":"2018","unstructured":"Tamiya H, Mitani A, Saito A, Ishimori T, Saito M, Isago H, Jo T, Yamauchi Y, Tanaka G, Nagase T. Exosomal MicroRNA expression profiling in patients with lung adenocarcinoma-associated malignant pleural effusion. Anticancer Res. 2018;38(12):6707\u201314.","journal-title":"Anticancer Res"},{"key":"2753_CR177","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2018.07.018","volume":"124","author":"P Hydbring","year":"2018","unstructured":"Hydbring P, De Petris L, Zhang Y, Brand\u00e9n E, Koyi H, Novak M, Kanter L, H\u00e5\u00e5g P, Hurley J, Tadigotla V, Zhu B, Skog J, Viktorsson K, Ekman S, Lewensohn R. Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. Lung Cancer. 2018;124:45\u201352.","journal-title":"Lung Cancer"},{"issue":"3","key":"2753_CR178","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3892\/ol.2017.5569","volume":"13","author":"H Dejima","year":"2017","unstructured":"Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 2017;13(3):1256\u201363.","journal-title":"Oncol Lett"},{"issue":"8","key":"2753_CR179","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.18632\/oncotarget.14369","volume":"8","author":"Q Liu","year":"2017","unstructured":"Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z, Xiang Y, Wu N, Wu L, Bai L, Li Y. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Oncotarget. 2017;8(8):13048\u201358.","journal-title":"Oncotarget"},{"issue":"16","key":"2753_CR180","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1177\/1535370220945987","volume":"245","author":"ZJ Zhang","year":"2020","unstructured":"Zhang ZJ, Song XG, Xie L, Wang KY, Tang YY, Yu M, Feng XD, Song XR. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer. Exp Biol Med (Maywood). 2020;245(16):1428\u201336.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2753_CR181","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-018-0949-y","volume":"19","author":"L Zhang","year":"2018","unstructured":"Zhang L, Hao C, Zhai R, Wang D, Zhang J, Bao L, Li Y, Yao W. Downregulation of exosomal let-7a-5p in dust exposed- workers contributes to lung cancer development. Respir Res. 2018;19(1):235.","journal-title":"Respir Res"},{"issue":"4","key":"2753_CR182","first-page":"469","volume":"14","author":"R Luo","year":"2021","unstructured":"Luo R, Liu H, Chen J. Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer. Int J Clin Exp Pathol. 2021;14(4):469\u201374.","journal-title":"Int J Clin Exp Pathol"},{"key":"2753_CR183","volume":"26","author":"Q Dong","year":"2020","unstructured":"Dong Q, Dong L, Liu S, Kong Y, Zhang M, Wang X. Tumor-derived exosomal eIF4E as a biomarker for survival prediction in patients with non-small cell lung cancer. Med Sci Monit. 2020;26: e923210.","journal-title":"Med Sci Monit"},{"issue":"11","key":"2753_CR184","first-page":"2650","volume":"21","author":"DL Yuwen","year":"2017","unstructured":"Yuwen DL, Sheng BB, Liu J, Wenyu W, Shu YQ. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017;21(11):2650\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"2753_CR185","volume":"35","author":"J Xia","year":"2021","unstructured":"Xia J, Luo M, Dai L, Wang L, Wang L, Zhu J. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer. J Clin Lab Anal. 2021;35(5): e23743.","journal-title":"J Clin Lab Anal"},{"key":"2753_CR186","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112963","volume":"150","author":"M Entezari","year":"2022","unstructured":"Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi M, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A, Nabavi N, Rabiee N, Hashemi M, Samarghandian S. Long non-coding RNAs and exosomal lncRNAs: potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022;150: 112963.","journal-title":"Biomed Pharmacother"},{"key":"2753_CR187","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cca.2019.11.031","volume":"504","author":"Z Chen","year":"2020","unstructured":"Chen Z, Lei T, Chen X, Gu J, Huang J, Lu B, Wang Z. Long non-coding RNA in lung cancer. Clin Chim Acta. 2020;504:190\u2013200.","journal-title":"Clin Chim Acta"},{"key":"2753_CR188","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2147\/CMAR.S365762","volume":"14","author":"L Chen","year":"2022","unstructured":"Chen L, Xie Y, Yu M, Gou Q. Long Noncoding RNAs in lung cancer: from disease markers to treatment roles. Cancer Manag Res. 2022;14:1771\u201382.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"2753_CR189","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbrc.2017.06.055","volume":"490","author":"R Zhang","year":"2017","unstructured":"Zhang R, Xia Y, Wang Z, Zheng J, Chen Y, Li X, Wang Y, Ming H. Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;490(2):406\u201314.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"2753_CR190","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41419-021-03928-w","volume":"12","author":"J Ni","year":"2021","unstructured":"Ni J, Zhang X, Li J, Zheng Z, Zhang J, Zhao W, Liu L. Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p\/RAC1 signalling axis in osteoclasts. Cell Death Dis. 2021;12(7):662.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2753_CR191","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/1878-0261.12188","volume":"12","author":"Y Xie","year":"2018","unstructured":"Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan W, Li J, Zhan Y, Wang L, Zhang S, Li S, Wang L, Xu S, Wang C. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol. 2018;12(5):648\u201358.","journal-title":"Mol Oncol"},{"issue":"6","key":"2753_CR192","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/carcin\/bgab034","volume":"42","author":"J Xian","year":"2021","unstructured":"Xian J, Zeng Y, Chen S, Lu L, Liu L, Chen J, Rao B, Zhao Z, Liu J, Xie C, Zhu L, Zhang D, Qiu F, Lu J, Yang L. Discovery of a novel linc01125 isoform in serum exosomes as a promising biomarker for NSCLC diagnosis and survival assessment. Carcinogenesis. 2021;42(6):831\u201341.","journal-title":"Carcinogenesis"},{"issue":"11","key":"2753_CR193","volume":"35","author":"P Han","year":"2021","unstructured":"Han P, Zhao J, Gao L. Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer. J Clin Lab Anal. 2021;35(11): e23979.","journal-title":"J Clin Lab Anal"},{"key":"2753_CR194","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cca.2017.10.027","volume":"475","author":"W Li","year":"2017","unstructured":"Li W, Li N, Kang X, Shi K. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer. Clin Chim Acta. 2017;475:152\u20136.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2753_CR195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10147-022-02129-5","volume":"27","author":"L Min","year":"2022","unstructured":"Min L, Zhu T, Lv B, An T, Zhang Q, Shang Y, Yu Z, Zheng L, Wang Q. Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer. Int J Clin Oncol. 2022;27(6):1013\u201324.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2753_CR196","doi-asserted-by":"crossref","first-page":"471","DOI":"10.7150\/ijbs.39123","volume":"16","author":"Y Tao","year":"2020","unstructured":"Tao Y, Tang Y, Yang Z, Wu F, Wang L, Yang L, Lei L, Jing Y, Jiang X, Jin H, Bai Y, Zhang L. Exploration of serum exosomal LncRNA TBILA and AGAP2-AS1 as promising biomarkers for diagnosis of non-small cell lung cancer. Int J Biol Sci. 2020;16(3):471\u201382.","journal-title":"Int J Biol Sci"},{"key":"2753_CR197","doi-asserted-by":"crossref","unstructured":"Ricordel C, Friboulet L, Facchinetti F, Soria JC. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Ann Oncol. 2018;29(suppl_1):i28-37.","DOI":"10.1093\/annonc\/mdx705"},{"issue":"1","key":"2753_CR198","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massagu\u00e9 J. Surviving at a distance: organ-specific metastasis. Trends Cancer. 2015;1(1):76\u201391.","journal-title":"Trends Cancer"},{"issue":"2","key":"2753_CR199","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ijc.30669","volume":"141","author":"DH Bach","year":"2017","unstructured":"Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer. 2017;141(2):220\u201330.","journal-title":"Int J Cancer"},{"key":"2753_CR200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","volume":"45","author":"N Milman","year":"2019","unstructured":"Milman N, Ginini L, Gil Z. Exosomes and their role in tumorigenesis and anticancer drug resistance. Drug Resist Updat. 2019;45:1\u201312.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"2753_CR201","volume":"10","author":"S Li","year":"2020","unstructured":"Li S, Yi M, Dong B, Jiao Y, Luo S, Wu K. The roles of exosomes in cancer drug resistance and its therapeutic application. Clin Transl Med. 2020;10(8): e257.","journal-title":"Clin Transl Med"},{"issue":"6","key":"2753_CR202","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.7150\/thno.51797","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K, Liu L, Hua Q, Zhao J, Liu J, Yang H, Huang G. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860\u201375.","journal-title":"Theranostics"},{"issue":"21","key":"2753_CR203","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-20-1192","volume":"80","author":"Y Lu","year":"2020","unstructured":"Lu Y, Liu Y, Oeck S, Zhang GJ, Schramm A, Glazer PM. Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway. Cancer Res. 2020;80(21):4655\u201367.","journal-title":"Cancer Res"},{"issue":"9","key":"2753_CR204","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00595-020-01976-x","volume":"50","author":"Y Azuma","year":"2020","unstructured":"Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, Shimizu K, Shirabe K, Kuwano H. Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells. Surg Today. 2020;50(9):1099\u2013106.","journal-title":"Surg Today"},{"issue":"1\u20134","key":"2753_CR205","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bbrc.2018.11.061","volume":"507","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Li M, Hu C. Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer. Biochem Biophys Res Commun. 2018;507(1\u20134):457\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"2753_CR206","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.2147\/IJN.S131516","volume":"12","author":"X Qin","year":"2017","unstructured":"Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D, Feng J. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine. 2017;12:3721\u201333.","journal-title":"Int J Nanomedicine"},{"issue":"17","key":"2753_CR207","doi-asserted-by":"crossref","first-page":"24510","DOI":"10.18632\/oncotarget.8229","volume":"7","author":"QY Chen","year":"2016","unstructured":"Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 2016;7(17):24510\u201326.","journal-title":"Oncotarget"},{"issue":"6","key":"2753_CR208","first-page":"3438","volume":"40","author":"Y Lei","year":"2018","unstructured":"Lei Y, Guo W, Chen B, Chen L, Gong J, Li W. Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer. Oncol Rep. 2018;40(6):3438\u201346.","journal-title":"Oncol Rep"},{"issue":"1","key":"2753_CR209","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-019-1202-z","volume":"20","author":"Y Yu","year":"2019","unstructured":"Yu Y, Abudula M, Li C, Chen Z, Zhang Y, Chen Y. Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC. Respir Res. 2019;20(1):217.","journal-title":"Respir Res"},{"issue":"5","key":"2753_CR210","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.apsb.2022.08.020","volume":"13","author":"E Zhang","year":"2023","unstructured":"Zhang E, Phan P, Zhao Z. Cellular nanovesicles for therapeutic immunomodulation: a perspective on engineering strategies and new advances. Acta Pharm Sin B. 2023;13(5):1789\u2013827.","journal-title":"Acta Pharm Sin B"},{"issue":"1\u20132","key":"2753_CR211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-019-03545-4","volume":"459","author":"A Familtseva","year":"2019","unstructured":"Familtseva A, Jeremic N, Tyagi SC. Exosomes: cell-created drug delivery systems. Mol Cell Biochem. 2019;459(1\u20132):1\u20136.","journal-title":"Mol Cell Biochem"},{"key":"2753_CR212","first-page":"281","volume":"10","author":"A Thakur","year":"2022","unstructured":"Thakur A, Parra DC, Motallebnejad P, Brocchi M, Chen HJ. Exosomes: small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater. 2022;10:281\u201394.","journal-title":"Bioact Mater"},{"issue":"7","key":"2753_CR213","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183\u201395.","journal-title":"Theranostics"},{"issue":"4","key":"2753_CR214","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/1568009617666170710120311","volume":"18","author":"X Wang","year":"2018","unstructured":"Wang X, Zhang H, Yang H, Bai M, Ning T, Li S, Li J, Deng T, Ying G, Ba Y. Cell-derived exosomes as promising carriers for drug delivery and targeted therapy. Curr Cancer Drug Targets. 2018;18(4):347\u201354.","journal-title":"Curr Cancer Drug Targets"},{"key":"2753_CR215","doi-asserted-by":"crossref","unstructured":"Fang Z, Ding Y, Xue Z, Li P, Li J, Li F. Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. Discov Oncol. 2022;13(1):1\u201317.","DOI":"10.1007\/s12672-022-00539-5"},{"issue":"1","key":"2753_CR216","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-022-01472-z","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Q, Zhang X, Huang H, Tang S, Chai Y, Xu Z, Li M, Chen X, Liu J, Yang C. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnology. 2022;20(1):279.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"2753_CR217","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","volume":"27","author":"W Meng","year":"2020","unstructured":"Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585\u201398.","journal-title":"Drug Deliv"},{"issue":"10","key":"2753_CR218","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1111\/cas.14181","volume":"110","author":"M Yu","year":"2019","unstructured":"Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, Lv S, Li W. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019;110(10):3173\u201382.","journal-title":"Cancer Sci"},{"issue":"1","key":"2753_CR219","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","volume":"371","author":"R Munagala","year":"2016","unstructured":"Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016;371(1):48\u201361.","journal-title":"Cancer Lett"},{"issue":"5","key":"2753_CR220","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.nano.2017.03.001","volume":"13","author":"AK Agrawal","year":"2017","unstructured":"Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem SS, Oben K, Munagala R, Bondada S, Gupta RC. Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine. 2017;13(5):1627\u201336.","journal-title":"Nanomedicine"},{"issue":"1","key":"2753_CR221","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2016.05.013","volume":"101","author":"F Aqil","year":"2016","unstructured":"Aqil F, Kausar H, Agrawal AK, Jeyabalan J, Kyakulaga AH, Munagala R, Gupta R. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol. 2016;101(1):12\u201321.","journal-title":"Exp Mol Pathol"},{"key":"2753_CR222","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.02.011","volume":"449","author":"F Aqil","year":"2019","unstructured":"Aqil F, Munagala R, Jeyabalan J, Agrawal AK, Kyakulaga AH, Wilcher SA, Gupta RC. Milk exosomes - Natural nanoparticles for siRNA delivery. Cancer Lett. 2019;449:186\u201395.","journal-title":"Cancer Lett"},{"issue":"1","key":"2753_CR223","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/10717544.2021.1951894","volume":"28","author":"Y Wang","year":"2021","unstructured":"Wang Y, Guo M, Lin D, Liang D, Zhao L, Zhao R, Wang Y. Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo. Drug Deliv. 2021;28(1):1510\u201323.","journal-title":"Drug Deliv"},{"issue":"1","key":"2753_CR224","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","volume":"14","author":"MS Kim","year":"2018","unstructured":"Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, Kabanov AV, Batrakova EV. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018;14(1):195\u2013204.","journal-title":"Nanomedicine"},{"issue":"3","key":"2753_CR225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","volume":"12","author":"MS Kim","year":"2016","unstructured":"Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655\u201364.","journal-title":"Nanomedicine"},{"key":"2753_CR226","doi-asserted-by":"crossref","unstructured":"Kandimalla R, Aqil F, Alhakeem SS, Jeyabalan J, Tyagi N, Agrawal A, Yan J, Spencer W, Bondada S and Gupta RC. Targeted oral delivery of paclitaxel using colostrum-derived exosomes. Cancers (Basel). 2021; 13(15).","DOI":"10.3390\/cancers13153700"},{"issue":"2","key":"2753_CR227","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1039\/C9NR09011H","volume":"12","author":"H Nie","year":"2020","unstructured":"Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F, Li F, Cheng Y, Mei H, Meng H, Jia L. Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale. 2020;12(2):877\u201387.","journal-title":"Nanoscale"},{"issue":"4","key":"2753_CR228","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ajps.2019.04.002","volume":"15","author":"J Bai","year":"2020","unstructured":"Bai J, Duan J, Liu R, Du Y, Luo Q, Cui Y, Su Z, Xu J, Xie Y, Lu W. Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells. Asian J Pharm Sci. 2020;15(4):461\u201371.","journal-title":"Asian J Pharm Sci"},{"issue":"11","key":"2753_CR229","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/1759-7714.14445","volume":"13","author":"X Lin","year":"2022","unstructured":"Lin X, Lin L, Wu J, Jiang W, Wu J, Yang J, Chen C. A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer. Thorac Cancer. 2022;13(11):1691\u2013702.","journal-title":"Thorac Cancer"},{"key":"2753_CR230","first-page":"6141857","volume":"2022","author":"W Gao","year":"2022","unstructured":"Gao W, Yang N, Yin C, Zeng Y, Zhu X. Engineered exosomes loaded with miR-563 inhibit lung cancer growth. J Oncol. 2022;2022:6141857.","journal-title":"J Oncol"},{"key":"2753_CR231","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2021.02.011","volume":"505","author":"R Munagala","year":"2021","unstructured":"Munagala R, Aqil F, Jeyabalan J, Kandimalla R, Wallen M, Tyagi N, Wilcher S, Yan J, Schultz DJ, Spencer W, Gupta RC. Exosome-mediated delivery of RNA and DNA for gene therapy. Cancer Lett. 2021;505:58\u201372.","journal-title":"Cancer Lett"},{"issue":"10","key":"2753_CR232","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1111\/1759-7714.13175","volume":"10","author":"D Hao","year":"2019","unstructured":"Hao D, Li Y, Zhao G, Zhang M. Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration. Thorac Cancer. 2019;10(10):1962\u201372.","journal-title":"Thorac Cancer"},{"key":"2753_CR233","doi-asserted-by":"crossref","unstructured":"Naseri M, Bozorgmehr M, Z\u00f6ller M, Ranaei Pirmardan E and Madjd Z, Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020; 9(1):1779991.","DOI":"10.1080\/2162402X.2020.1779991"},{"issue":"9","key":"2753_CR234","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13238-021-00863-6","volume":"13","author":"A Thakur","year":"2022","unstructured":"Thakur A, Ke X, Chen YW, Motallebnejad P, Zhang K, Lian Q, Chen HJ. The mini player with diverse functions: extracellular vesicles in cell biology, disease, and therapeutics. Protein Cell. 2022;13(9):631\u201354.","journal-title":"Protein Cell"},{"issue":"11","key":"2753_CR235","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s11095-021-03143-4","volume":"39","author":"MN Huda","year":"2022","unstructured":"Huda MN, Nurunnabi M. Potential application of exosomes in vaccine development and delivery. Pharm Res. 2022;39(11):2635\u201371.","journal-title":"Pharm Res"},{"issue":"3","key":"2753_CR236","volume":"9","author":"Y Yao","year":"2014","unstructured":"Yao Y, Wang C, Wei W, Shen C, Deng X, Chen L, Ma L, Hao S. Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities. PLoS One. 2014;9(3): e91463.","journal-title":"PLoS One"},{"issue":"3","key":"2753_CR237","volume":"7","author":"EY Lee","year":"2012","unstructured":"Lee EY, Park KS, Yoon YJ, Lee J, Moon HG, Jang SC, Choi KH, Kim YK, Gho YS. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE. 2012;7(3): e33330.","journal-title":"PLoS ONE"},{"issue":"5","key":"2753_CR238","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/10428190500376191","volume":"47","author":"N Bu","year":"2006","unstructured":"Bu N, Li QL, Feng Q, Sun BZ. Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk Lymphoma. 2006;47(5):913\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2753_CR239","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107.","journal-title":"J Hematol Oncol"},{"key":"2753_CR240","doi-asserted-by":"crossref","unstructured":"Khadela A, Chavda VP, Postwala H, Ephraim R, Apostolopoulos V and Shah Y, Configuring therapeutic aspects of immune checkpoints in lung cancer. Cancers (Basel). 2023; 15(2).","DOI":"10.3390\/cancers15020543"},{"issue":"2","key":"2753_CR241","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.","journal-title":"Cell"},{"issue":"Pt 3","key":"2753_CR242","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","volume":"86","author":"S Gaikwad","year":"2022","unstructured":"Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 3):137\u201350.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2753_CR243","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"1","key":"2753_CR244","first-page":"56","volume":"8","author":"C Xing","year":"2021","unstructured":"Xing C, Li H, Li RJ, Yin L, Zhang HF, Huang ZN, Cheng Z, Li J, Wang ZH, Peng HL. The roles of exosomal immune checkpoint proteins in tumors. Mil Med Res. 2021;8(1):56.","journal-title":"Mil Med Res"},{"key":"2753_CR245","doi-asserted-by":"crossref","unstructured":"Raimondo S, Pucci M, Alessandro R, Fontana S. Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives. Int J Mol Sci. 2020;21(7):2286.","DOI":"10.3390\/ijms21072286"},{"key":"2753_CR246","doi-asserted-by":"crossref","unstructured":"Takeda Y, Kobayashi S, Kitakaze M, Yamada D, Akita H, Asai A, Konno M, Arai T, Kitagawa T, Ofusa K, Yabumoto M, Hirotsu T, A. Vecchione, Taniguchi M, Doki Y, Eguchi H, Ishii H, Immuno-surgical management of pancreatic cancer with analysis of cancer exosomes. Cells. 2020;9(7):1645.","DOI":"10.3390\/cells9071645"},{"key":"2753_CR247","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","volume":"121","author":"E Koh","year":"2017","unstructured":"Koh E, Lee EJ, Nam GH, Hong Y, Cho E, Yang Y, Kim IS. Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis. Biomaterials. 2017;(12):121\u20139.","journal-title":"Biomaterials"},{"issue":"7","key":"2753_CR248","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 1","key":"2753_CR249","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y. PD-1\/PD-L1 Blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31-s41.","journal-title":"Oncologist"},{"issue":"5","key":"2753_CR250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","volume":"25","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818\u201330.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2753_CR251","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cei\/uxac045","volume":"208","author":"Y Wang","year":"2022","unstructured":"Wang Y, Niu X, Cheng Y, Zhang Y, Xia L, Xia W, Lu S. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. Clin Exp Immunol. 2022;208(3):316\u201322.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2753_CR252","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41598-021-87575-3","volume":"11","author":"Y Shimada","year":"2021","unstructured":"Shimada Y, Matsubayashi J, Kudo Y, Maehara S, Takeuchi S, Hagiwara M, Kakihana M, Ohira T, Nagao T, Ikeda N. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci Rep. 2021;11(1):7830.","journal-title":"Sci Rep"},{"issue":"7","key":"2753_CR253","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/cam4.3649","volume":"10","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021;10(7):2216\u201331.","journal-title":"Cancer Med"},{"issue":"11","key":"2753_CR254","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1245\/s10434-019-07431-7","volume":"26","author":"Y Fan","year":"2019","unstructured":"Fan Y, Che X, Qu J, Hou K, Wen T, Li Z, Li C, Wang S, Xu L, Liu Y, Qu X. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol. 2019;26(11):3745\u201355.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2753_CR255","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","volume":"10","author":"Y Geng","year":"2021","unstructured":"Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X. Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(4):1222\u201339.","journal-title":"Cancer Med"},{"issue":"1","key":"2753_CR256","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","volume":"17","author":"C Li","year":"2019","unstructured":"Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D, Liu H. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J Transl Med. 2019;17(1):355.","journal-title":"J Transl Med"},{"issue":"5","key":"2753_CR257","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cllc.2018.04.014","volume":"19","author":"Y Okuma","year":"2018","unstructured":"Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, Homma S. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):410-417.e411.","journal-title":"Clin Lung Cancer"},{"key":"2753_CR258","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J. Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients. Front Immunol. 2021;12: 665133.","journal-title":"Front Immunol"},{"key":"2753_CR259","volume":"79","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jin W, Xu K, Zheng X, Zhou Y, Luo M, Yan C, Zheng X, Jin E. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer. Tissue Cell. 2022;79: 101941.","journal-title":"Tissue Cell"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02753-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:43:32Z","timestamp":1700624612000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":259,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02753-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}